Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 |
| clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03307148 | Stromal TARgeting for PAncreatic Cancer (STAR_PAC)(STAR_PAC) | completed | Phase 1 | 29 | Barts & The London NHS TrustOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT04229537 | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC | unknown | Phase 1 | 60 | Sinocelltech Ltd.INDUSTRY | 0 | Jan 18, 2020 | clinicaltrials |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | terminated | Phase 1 | 21 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01445405 | Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02881125 | Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma | completed | Phase 1 | 2 | University of WashingtonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00011778 | PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma(NUANCE) | terminated | Phase 1 | 1 | University of UtahOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 175 | Celldex TherapeuticsINDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | terminated | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Dec 6, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide | terminated | Phase 1 / Phase 2 | 22 | CelgeneINDUSTRY | 2 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | withdrawn | Phase 1 | 0 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | completed | Phase 1 | 128 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03855358 | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00923169 | Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | terminated | Phase 1 | 18 | CelgeneINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | terminated | Phase 1 | 6 | Virginia Commonwealth UniversityOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02620800 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer(FABLOx) | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00257738 | 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 17 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 28, 2020source: clinicaltrials